<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248416</url>
  </required_header>
  <id_info>
    <org_study_id>180984</org_study_id>
    <nct_id>NCT01248416</nct_id>
  </id_info>
  <brief_title>Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature</brief_title>
  <acronym>ThrasherAI</acronym>
  <official_title>A Randomized Controlled Trial Of The Use Of Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When treating very short children in puberty we are time-limited, as sex hormones cause the
      growth plates to fuse and growth to end. Growth Hormone (GH), plus drugs that stop puberty,
      increase height potential, but leave children sexually infantile at a critical time in
      development. Human and animal data show that estrogen, in females and males, is a principal
      regulator of the fusion of the growth plate in puberty. Using aromatase inhibitors (AIs),
      which block testosterone to estrogen conversion, in boys with different growth disorders, we
      have shown that AIs may have beneficial effects enhancing height potential in growth-retarded
      males, without affecting their puberty. However, no direct comparison of the effect of AIs
      alone vs. conventional GH treatment has been done to date. This study will assess the effect
      of AIs alone, GH alone and combination treatment in enhancing height potential in adolescent
      boys with idiopathic short stature.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Height</measure>
    <time_frame>0 to 24 months</time_frame>
    <description>Differences in height gains</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Predicted Height</measure>
    <time_frame>0 to 24 months</time_frame>
    <description>Primary efficacy end point: change in predicted height (cm) from baseline at 24 months based on change in bone age (years)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Density z Score Adjusted for Height</measure>
    <time_frame>0 to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lean Body Mass</measure>
    <time_frame>0 to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>0 to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGF-I Concentrations</measure>
    <time_frame>0 to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Testosterone</measure>
    <time_frame>0 to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estradiol</measure>
    <time_frame>0 to 24 months</time_frame>
    <description>Those taking AI alone or AI/GH combined were grouped by type, either anastrozole or letrozole.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estrone</measure>
    <time_frame>0 to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Idiopathic Short Stature</condition>
  <arm_group>
    <arm_group_label>Aromatase Inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Growth Hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aromatase Inhibitor and Growth Hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitor</intervention_name>
    <arm_group_label>Aromatase Inhibitor</arm_group_label>
    <arm_group_label>Aromatase Inhibitor and Growth Hormone</arm_group_label>
    <other_name>Arimidex (Anastrozole)</other_name>
    <other_name>Femara (Letrozole)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <arm_group_label>Aromatase Inhibitor and Growth Hormone</arm_group_label>
    <arm_group_label>Growth Hormone</arm_group_label>
    <other_name>Nutropin (Somatropin)</other_name>
    <other_name>Genotropin (Somatropin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitor and Growth Hormone</intervention_name>
    <arm_group_label>Aromatase Inhibitor and Growth Hormone</arm_group_label>
    <other_name>Arimidex (Anastrozole)</other_name>
    <other_name>Femara (Letrozole)</other_name>
    <other_name>Nutropin (Somatropin)</other_name>
    <other_name>Genotropin (Somatropin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males: Ages: 12 - less than 18 years.

          -  Bone age less than 14 Â½ years at study initiation.

          -  Presence of puberty.

          -  Idiopathic short stature will be defined as a short child equal or less than -2SD for
             height, with normal GH responses to stimuli (&gt; or = 5ng/ml to at least 2
             secretagogues) or a normal IGF-I and BP-3, normal body proportions and no other
             identifiable growth pathology.

          -  Accurate growth data for at least 6 months at baseline is available.

        Exclusion Criteria:

          -  Chronic illnesses.

          -  Chronic use of glucocorticosteroids.

          -  Previous use of hormonal treatment with AIs, sex steroids or GH in the preceding 6
             months.

          -  Birth weight small for gestational age (SGA).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelly Mauras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Clinic Jacksonville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic- Jefferson</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veronica Mericq, MD</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mauras N, Ross JL, Gagliardi P, Yu YM, Hossain J, Permuy J, Damaso L, Merinbaum D, Singh RJ, Gaete X, Mericq V. Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature. J Clin Endocrinol Metab. 2016 Dec;101(12):4984-4993. Epub 2016 Oct 6.</citation>
    <PMID>27710241</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <results_first_submitted>October 29, 2017</results_first_submitted>
  <results_first_submitted_qc>May 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2018</results_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nemours Children's Clinic</investigator_affiliation>
    <investigator_full_name>Nelly Mauras</investigator_full_name>
    <investigator_title>Chief, Division of Endocrinology, Diabetes &amp; Metabolism</investigator_title>
  </responsible_party>
  <keyword>Aromatase</keyword>
  <keyword>Growth</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Anastrozole</keyword>
  <keyword>GH</keyword>
  <keyword>Children</keyword>
  <keyword>Puberty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aromatase Inhibitor</title>
          <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
        </group>
        <group group_id="P2">
          <title>Growth Hormone</title>
          <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
        </group>
        <group group_id="P3">
          <title>Aromatase Inhibitor and Growth Hormone</title>
          <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aromatase Inhibitor</title>
          <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
        </group>
        <group group_id="B2">
          <title>Growth Hormone</title>
          <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
        </group>
        <group group_id="B3">
          <title>Aromatase Inhibitor and Growth Hormone</title>
          <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="1.0"/>
                    <measurement group_id="B2" value="14.1" spread="1.2"/>
                    <measurement group_id="B3" value="14.0" spread="1.1"/>
                    <measurement group_id="B4" value="14.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Height</title>
        <description>Differences in height gains</description>
        <time_frame>0 to 24 months</time_frame>
        <population>Differences in height gains from 0 to 24 months; Of the 76 Subjects, 65 completed all procedures at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Growth Hormone</title>
            <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
          </group>
          <group group_id="O3">
            <title>Aromatase Inhibitor and Growth Hormone</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Height</title>
          <description>Differences in height gains</description>
          <population>Differences in height gains from 0 to 24 months; Of the 76 Subjects, 65 completed all procedures at 24 months.</population>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="0.8"/>
                    <measurement group_id="O2" value="17.1" spread="0.9"/>
                    <measurement group_id="O3" value="18.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.006</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Predicted Height</title>
        <description>Primary efficacy end point: change in predicted height (cm) from baseline at 24 months based on change in bone age (years)</description>
        <time_frame>0 to 24 months</time_frame>
        <population>Of the 76 Subjects, 65 completed all procedures at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Growth Hormone</title>
            <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
          </group>
          <group group_id="O3">
            <title>Aromatase Inhibitor and Growth Hormone</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Predicted Height</title>
          <description>Primary efficacy end point: change in predicted height (cm) from baseline at 24 months based on change in bone age (years)</description>
          <population>Of the 76 Subjects, 65 completed all procedures at 24 months.</population>
          <units>centimeters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.0"/>
                    <measurement group_id="O2" value="4.9" spread="0.9"/>
                    <measurement group_id="O3" value="7.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Density z Score Adjusted for Height</title>
        <time_frame>0 to 24 months</time_frame>
        <population>Of the 76 Subjects, 65 completed all procedures at 24 months, however, 2 Subjects had a screw/pin in their leg/hip at the 24 month visit, and therefore, could not have a DEXA scan performed (N=63).</population>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Growth Hormone</title>
            <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
          </group>
          <group group_id="O3">
            <title>Aromatase Inhibitor and Growth Hormone</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Density z Score Adjusted for Height</title>
          <population>Of the 76 Subjects, 65 completed all procedures at 24 months, however, 2 Subjects had a screw/pin in their leg/hip at the 24 month visit, and therefore, could not have a DEXA scan performed (N=63).</population>
          <units>z-score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.061" spread="0.313"/>
                    <measurement group_id="O2" value="-0.586" spread="0.244"/>
                    <measurement group_id="O3" value="-0.605" spread="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.906</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lean Body Mass</title>
        <time_frame>0 to 24 months</time_frame>
        <population>Of the 76 Subjects, 65 completed all procedures at 24 months, however, 2 Subjects had a screw/pin in their leg/hip at the 24 month visit, and therefore, could not have a DEXA scan performed (N=63).</population>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Growth Hormone</title>
            <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
          </group>
          <group group_id="O3">
            <title>Aromatase Inhibitor and Growth Hormone</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lean Body Mass</title>
          <population>Of the 76 Subjects, 65 completed all procedures at 24 months, however, 2 Subjects had a screw/pin in their leg/hip at the 24 month visit, and therefore, could not have a DEXA scan performed (N=63).</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" spread="1.6"/>
                    <measurement group_id="O2" value="42.0" spread="1.3"/>
                    <measurement group_id="O3" value="46.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index</title>
        <time_frame>0 to 24 months</time_frame>
        <population>Of the 76 Subjects, 65 completed all procedures at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Growth Hormone</title>
            <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
          </group>
          <group group_id="O3">
            <title>Aromatase Inhibitor and Growth Hormone</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index</title>
          <population>Of the 76 Subjects, 65 completed all procedures at 24 months.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.3"/>
                    <measurement group_id="O2" value="1.7" spread="0.4"/>
                    <measurement group_id="O3" value="2.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IGF-I Concentrations</title>
        <time_frame>0 to 24 months</time_frame>
        <population>Of the 76 Subjects, 65 completed all procedures at 24 months, however, 1 Subject, did not have IGF-1 results available for the 24 month visit (N=64).</population>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Growth Hormone</title>
            <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
          </group>
          <group group_id="O3">
            <title>Aromatase Inhibitor and Growth Hormone</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IGF-I Concentrations</title>
          <population>Of the 76 Subjects, 65 completed all procedures at 24 months, however, 1 Subject, did not have IGF-1 results available for the 24 month visit (N=64).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" spread="14"/>
                    <measurement group_id="O2" value="280" spread="16"/>
                    <measurement group_id="O3" value="303" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Testosterone</title>
        <time_frame>0 to 24 months</time_frame>
        <population>Of the 76 Subjects, 65 completed all procedures at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Growth Hormone</title>
            <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
          </group>
          <group group_id="O3">
            <title>Aromatase Inhibitor and Growth Hormone</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Testosterone</title>
          <population>Of the 76 Subjects, 65 completed all procedures at 24 months.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="737" spread="79"/>
                    <measurement group_id="O2" value="372" spread="33"/>
                    <measurement group_id="O3" value="668" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estradiol</title>
        <description>Those taking AI alone or AI/GH combined were grouped by type, either anastrozole or letrozole.</description>
        <time_frame>0 to 24 months</time_frame>
        <population>Of the 51 AI alone or AI/GH combined Subjects, 41 completed all procedures at 24 months, however, 1 Subject did not have Estrone results available for the 24 month visit (N=40).</population>
        <group_list>
          <group group_id="O1">
            <title>Anastrozole</title>
            <description>Anastrozole 1mg for 2 to 3 years .</description>
          </group>
          <group group_id="O2">
            <title>Letrozole</title>
            <description>Letrozole 2.5mg daily orally for 2 to 3 years .</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estradiol</title>
          <description>Those taking AI alone or AI/GH combined were grouped by type, either anastrozole or letrozole.</description>
          <population>Of the 51 AI alone or AI/GH combined Subjects, 41 completed all procedures at 24 months, however, 1 Subject did not have Estrone results available for the 24 month visit (N=40).</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="1"/>
                    <measurement group_id="O2" value="4" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estrone</title>
        <time_frame>0 to 24 months</time_frame>
        <population>Of the 76 Subjects, 65 completed all procedures at 24 months, however, 1 Subject, did not have Estrone results available for the 24 month visit (N=64).</population>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Growth Hormone</title>
            <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
          </group>
          <group group_id="O3">
            <title>Aromatase Inhibitor and Growth Hormone</title>
            <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estrone</title>
          <population>Of the 76 Subjects, 65 completed all procedures at 24 months, however, 1 Subject, did not have Estrone results available for the 24 month visit (N=64).</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.7"/>
                    <measurement group_id="O2" value="6.1" spread="0.9"/>
                    <measurement group_id="O3" value="-0.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aromatase Inhibitor</title>
          <description>Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
Aromatase Inhibitor</description>
        </group>
        <group group_id="E2">
          <title>Growth Hormone</title>
          <description>Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Growth Hormone</description>
        </group>
        <group group_id="E3">
          <title>Aromatase Inhibitor and Growth Hormone</title>
          <description>Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
Aromatase Inhibitor
Growth Hormone
Aromatase Inhibitor and Growth Hormone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Slipped capital femoral epiphysis (SCFE)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tibial Fracture and Torn Meniscus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Back Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Self Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular Torsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nelly Mauras</name_or_title>
      <organization>Nemours Children's Clinic</organization>
      <phone>904-697-3674</phone>
      <email>nmauras@nemours.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

